<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/CytomX-Therapeutics-Inc-US23284F1057">CytomX Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/07/3290623/37704/en/cytomx-therapeutics-announces-q1-2026-financial-results-and-provides-business-update.html">CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update</a>
    </div>

      <div class="me-0 me-md-5">
        - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose selection and potential registrational trial in late line CRC - - Varseta-M Phase 1 study evaluatin...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/CytomX-Therapeutics-Inc-US23284F1057">CytomX Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/30/3284802/37704/en/cytomx-therapeutics-to-report-first-quarter-2026-financial-results-on-may-7-2026.html">CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday, May 7, 2026, after the close of U.S. markets.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/CytomX-Therapeutics-Inc-US23284F1057">CytomX Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray"></div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4686420-ccytomx-therapeutics-more-than-one-masked-immunotherapy-company">https://seekingalpha.com/article/4686420-ccytomx-therapeutics-more-than-one-masked-immunotherapy-company</a>
    </div>

      <div class="me-0 me-md-5">
        
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/CytomX-Therapeutics-Inc-US23284F1057">CytomX Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray"></div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4686420-ccytomx-therapeutics-more-than-one-masked-immunotherapy-company">https://seekingalpha.com/article/4686420-ccytomx-therapeutics-more-than-one-masked-immunotherapy-company</a>
    </div>

      <div class="me-0 me-md-5">
        
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/CytomX-Therapeutics-Inc-US23284F1057/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>